Clinical Trials Logo
  1. Home
  2. Uveitis
  3. NCT02357238
  4. Details
NCT02357238 Clinical Trial

Genetics of Uveitis

Uveitis Clinical Trial

Official title:
Genetics of Uveitis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02357238
Other study ID # 11-087
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 2011
Est. completion date January 2030

Study information
Verified date February 2024
Source The Cleveland Clinic
Contact Kimberly M Baynes, BSN, RN, COA
Phone 216-444-2566
Email baynesk@ccf.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.

Recruitment information / eligibility
Status Recruiting
Enrollment 1500
Est. completion date January 2030
Est. primary completion date January 2030
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - Any patient above with the diagnosis of uveitis. - Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis. Exclusion Criteria: - Patients who are unable to give consent - Patients in whom an adequated blood sample can not be obtained.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Cleveland Clinic Foundation Cleveland Ohio

Sponsors (1)
Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Non infectious uveitis Distinct uveitis conditions will have a polymorphism association or specific mutation. 5 years
Secondary Infectious uveitis Infectious uveitis (such as herpes associated uveitis, toxoplasmosis retinochoroiditis) will have specific polymorphisms/mutations in innate immune system genes which predispose the patient to infectious uveitis. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study